Attached files
| file | filename |
|---|---|
| EX-10.11 - EX-10.11 - Allogene Therapeutics, Inc. | allo-20191231xex1011.htm |
| 10-K - 10-K - Allogene Therapeutics, Inc. | allo-20191231.htm |
| EX-32.2 - EX-32.2 - Allogene Therapeutics, Inc. | allo-20191231xex322.htm |
| EX-31.2 - EX-31.2 - Allogene Therapeutics, Inc. | allo-20191231xex312.htm |
| EX-31.1 - EX-31.1 - Allogene Therapeutics, Inc. | allo-20191231xex311.htm |
| EX-23.1 - EX-23.1 - Allogene Therapeutics, Inc. | allo-20191231xex231.htm |
| EX-10.15 - EX-10.15 - Allogene Therapeutics, Inc. | allo-20191231xex1015.htm |
| EX-10.7 - EX-10.7 - Allogene Therapeutics, Inc. | allo-2019x1231xex107.htm |
| EX-4.3 - EX-4.3 - Allogene Therapeutics, Inc. | allo-20191231xex43.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Allogene Therapeutics, Inc. (the “Company”) on Form 10-K for the fiscal year ended December 31, 2019, to which this Certification is attached as Exhibit 32.1, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David Chang, M.D., Ph.D., President and Chief Executive Officer of the Company certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1)The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
| Date: February 27, 2020 | By: | /s/ David Chang, M.D., Ph.D. | ||||||
David Chang, M.D., Ph.D. President and Chief Executive Officer (Principal Executive Officer) | ||||||||
This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Allogene Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.